20020678774

21 NOV 2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 November 2001 (29.11.2001)

PCT

(10) International Publication Number
WO 01/89616 A1

(51) International Patent Classification[7]: A61M 15/00, B65D 83/14, 81/26

(21) International Application Number: PCT/GB01/02256

(22) International Filing Date: 22 May 2001 (22.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0012522.9 23 May 2000 (23.05.2000) GB
0031502.8 22 December 2000 (22.12.2000) GB

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **CRIPPS, Alan, Leslie** [GB/GB]; Glaxo Wellcome plc, Park Road, Ware, Hertfordshire SG12 0DP (GB). **GODFREY, Anne, Pauline** [GB/GB]; Glaxo Wellcome plc, Park Street, Ware, Hertfordshire SG12 0DP (GB). **OTTOLANGUI, David, Michael** [GB/GB]; Glaxo Wellcome plc, Park Street, Ware, Hertfordshire SG12 0DP (GB). **WARBY, Richard, John** [GB/GB]; Bespak Ltd., Bergen Way, King's Lynn, Norfolk PE30 2JJ (GB).

(74) Agent: **TEUTEN, Andrew**; GlaxoSmithKline, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

ACTION

WO 01/89616 A1

(54) Title: AEROSOL CONTAINER FOR FORMULATIONS OF SALMETEROL XINAFOATE

(57) Abstract: The invention relates inter alia to a container sealed with a valve, which contains a pharmaceutical aerosol formulation comprising (A) particulate salmeterol xinafoate in suspension in (B) a liquefied propellant gas which is 1,1,1,2,3,3,3-heptafluoro-n-propane or 1,1,1,2-tetrafluoroethane and mixtures thereof; said container characterised in that the formulation is substantially anhydrous and remains so over a period of 12 months when stored at 25 °C and at relative humidity of 60 %. Preferably the valve is characterised in that it contains one or more valve seals substantially constructed from a polymer of ethylene propylene diene monomer (EPDM).